Health

CDC director files to sell her entire Butterfly (BFLY) stake one day after the 22% pop

Erica Schwartz's Form 144 covers all 401,699 shares she reported owning, marked at $10, the morning after Needham's initiation sent the stock up 22%. The CEO's sales were automatic or pre-scheduled, and he still holds 7.35 million shares.

Vincent JiangVincent Jiangthree-minute read
Share
Official portrait of CDC director Erica Schwartz, smiling, in a blue blazer
1 / 6Slide 1 of 6
Erica Schwartz, confirmed as CDC director on 5 August 2026, filed to sell her entire recorded Butterfly Network stake the morning after a Buy initiation sent the stock up 22 percent.

The director who left for the CDC is selling everything on record

Erica Schwartz stepped off Butterfly Network's−8.55% — Butterfly Network, down 8.55 percent today board on 5 August 2026, the day the Senate confirmed her to run the CDC 45. On 22 September, the day a Buy initiation sent the stock up 21.99% to $9.93 310, she sold 78,679 Class A shares for $786,790 1. The next morning her Form 144 reached EDGAR: 323,020 more shares, aggregate market value $3,230,200 1.

Her most recent ownership filing, from 22 June, reported 401,699 shares 9. The completed sale plus the pending block equals that position exactly. Rule 144 asks no reason, and none is given 1.

The bull case is 2030 money with nothing shipped

Needham's David Saxon opened at Buy with a $10 target, a sum-of-the-parts at roughly 16 times the firm's 2027 sales estimate 3. The model carries an estimated $300 million of Midjourney licensing revenue at 2030 and about $25 million from Mendaera, and concedes no Embedded partnership has launched a commercial product; roughly two-thirds of sales are still the legacy probe business 3. Sixteen times sales across 244.9 million shares implies about $150 million of 2027 revenue, a third more than the trailing four quarters delivered 111.

Affiliates put 685,000 shares on the tape

President, CEO and chairman Joseph DeVivo disclosed $2.07 million of July and August sales, then filed a fresh 2,811-share notice the afternoon of the pop 2. Counting Schwartz's 401,699 shares, disclosed affiliate supply since July runs to about 685,000 shares, 0.28 percent of the 244,858,246 outstanding 12. Small against the float. The signal is who sold, and when.

Butterfly insider blocks grew into the pop, and the biggest is still pending

  • Gross proceeds ($M)
  • Estimate
$0M$1M$2M$3M$4MDeVivo, 20 JulDeVivo, 10 AugSchwartz, 22 SepSchwartz, 23 Sep (planned)$0.79M
Data
Gross proceeds ($M)
DeVivo, 20 Jul$1.39M
DeVivo, 10 Aug$0.68M
Schwartz, 22 Sep$0.79M
Schwartz, 23 Sep (planned) (estimate)$3.23M
Gross proceeds per disclosed Rule 144 block, July to September 2026, in millions of US dollars. The 23 September bar is Schwartz's intended sale at its stated aggregate market value; the other three are completed sales. From SEC Form 144 notices filed 22 and 23 September 2026.1,2

The biggest block is the one still pending

Schwartz's 22 September sale printed near $9.99 a share, within half a percent of the $10.05 52-week high 110. The pending block is marked at exactly $10. Her notice lists five vesting tranches running back to June 2024 and no Rule 10b5-1 plan date; DeVivo's carries one, adopted 12 December 2025 12. The bull case is priced in 2030 dollars; the insider paper cleared at $10.

The counter-read: the CEO is staying

DeVivo's July sale of 211,798 shares at an average $6.56 was a sell-to-cover for RSU taxes, automatic and not at his discretion, his Form 4 states 7. The August block ran under the December plan, adopted long before the run 8. He still held 7,353,700 shares after gifting 250,000 to trusts for his children, about $69 million at Wednesday's $9.42 close 63. Buyers met the tape too: 33 hedge funds held $425 million of the stock at the end of June, up from $171 million a quarter earlier 10.

What settles it

Earnings are due around 30 October, guided to $26 to $30 million of revenue and adjusted EBITDA between negative $9 million and negative $6 million 10. Butterfly has lost money in each of the last eight quarters while cash fell to $124.7 million at midyear 11. The tells are the first commercial Embedded shipment, and the Form 4 that follows her last 323,020 shares out the door.

Revenue is growing, but Butterfly has lost money for ten straight quarters

  • Revenue ($M)
  • Net income ($M)
-$40M-$20M$0M$20M$40MQ2 '24Q4 '24Q2 '25Q4 '25Q2 '26$32.61M-$12.91M
Data
Revenue ($M)Net income ($M)
Q1 '24$17.66M-$21.76M
Q2 '24$21.49M-$15.71M
Q3 '24$20.56M-$16.92M
Q4 '24$22.35M-$18.1M
Q1 '25$21.23M-$13.97M
Q2 '25$23.38M-$13.83M
Q3 '25$21.49M-$33.97M
Q4 '25$31.51M-$15.29M
Q1 '26$26.53M-$12.68M
Q2 '26$32.61M-$12.91M
Quarterly revenue and net income, Q1 2024 to Q2 2026, in millions of US dollars. Butterfly has posted a net loss in each of the last ten quarters, including the eight cited in the story. From Sharadar quarterly fundamentals, from Butterfly Network's SEC filings.11

Get Health by email, free

AI in medicine, pharma and biotech. In our daily email, every weekday.

Loading BFLY

Reader comments

0 comments

    More in Health

    All in this topic →

    Health

    OpenAI lets clinicians prescribe from ChatGPT through Photon, moving pharmacy choice to patients

    For Evidenced, the healthcare venture firm that bets on U.S. regulatory tailwinds, the launch adds a second engine: market-driven distribution through OpenAI's clinician base. The free window through December 31 is the first adoption test for its portfolio company Photon.

    Health

    Kaiser's 1,200-scan trial found AI echo drafts matched clinicians and halved read time

    The Permanente Medical Group ran the randomized trial of EchoPrime itself and found the AI drafts matched clinician drafts while cutting cardiologist read time nearly in half. Days later it launched Permanentech, its own vehicle to commercialize clinical AI, so the buy-or-build question just got a benchmark.

    Health

    Eli Lilly Agreed to Buy Calytrix Bio for Up to $1.5 Billion, Its Latest Deal in a $32 Billion Year

    A $32 billion acquisition year rests on an $11 billion quarterly cash engine, but the deal headlines are "up to" figures and the balance sheet is already thinning. Whose money moves: anyone holding LLY at 31 times forward earnings into December 7 and January.

    Health

    GE HealthCare's manganese MRI agent matched gadolinium, a route past China's rare earths

    About 65 million contrast-enhanced MRI scans a year run on gadolinium, a rare earth whose export China licenses. A manganese substitute that matched the incumbent in GE HealthCare's Phase 2 trial opens a route off that chain for the company's highest-margin segment, if Phase 3 holds.

    Health

    Abridge lost AI scribing to Microsoft and Epic; its next market has a $100 million price from Wolters Kluwer

    Microsoft and Epic took two of every three new AI-scribe dollars this year, and Abridge, which built that market, is selling what comes after the note. The decision-support category it is moving into just got a public price, Wolters Kluwer's $100 million AgileMD deal, and that price is what Abridge's $6.69 billion private mark has to outrun.

    Health

    CMS's CRUSH rule reaches past Medicare into Molina's $42 billion Medicaid book

    The November 18 rout priced the proposal as a UnitedHealth-Humana Medicare bill. Molina is leaving that business, so for it the rule's weight falls on the Medicaid audit duties covering the $42 billion premium book that carries its $9.50 2027 earnings framework.

    Subscribe to TheInference for free